Company: TELO
Filing Date: 2025-11-10
Form Type: 10-Q
Source: 0001493152-25-021496
Chunk: 17

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-11-10
Form: 10-Q
Item: Item 1
Chunk 17
---
 measure of segment assets is reported on the balance sheets as total
assets.

The
table below provides information about the Company’s revenue, significant segment expenses and other segment expenses.

 Schedule
of segment information

    Three Months Ended
                                                                                Septembder 30,  
    Nine Months Ended
                                                                                September 30, 

    2025  
    2024  
    2025  
    2024 
  
    Revenues 
    $-  
    $-  
    $-  
    $- 
  
    Less segment expenses: 

    Operating costs: 

    General and administrative expenses 
     386,951  
     5,378,744  
     7,264,808  
     6,999,981 
  
    Related party travel costs 
     -  
     -  
     -  
     370,500 
  
    Research and development expenses 
     759,525  
     627,434  
     1,139,360  
     1,966,258 
  
    Total operating costs 
     1,146,476  
     6,006,178  
     8,404,168  
     9,336,739 
  
    Interest income (expense), net 
     44,182  
     15,445  
     52,156  
     (4,297,604)
  
    Segment net loss 
    $(1,102,294) 
    $(5,990,733) 
    $(8,352,012) 
    $(13,634,343)

Note
7. Subsequent Events

ATM
Offering

On
October 9, 2025, the Company sold a total of 550,000 shares of its common stock, no par value, in block sales to institutional investors,
at an average price of $1.90 per share, through its at-the-market equity offering facility. Net proceeds totaled $1,003,200, after deducting
fees and expenses. The trades for the Offering were facilitated through Rodman & Renshaw, via the StockBlock platform.

Letter
of Intent

On
October 17, 2025, the Company executed a binding Letter of Intent (the “LOI”) to acquire TELI Pharmaceuticals, Inc., a
related party company,